AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 82 min read$BFRI

Biofrontera Files SNDA To Expand Ameluz Use In Actinic Keratosis; Stock Down

Biofrontera Inc. (BFRI) filed an sNDA to expand Ameluz's use for actinic keratosis, supported by positive Phase 3 trial results. The application aims to treat mild-to-moderate AK on extremities, neck, and trunk. Ameluz, combined with BF-RhodoLED lamps, showed 45.6% complete lesion clearance vs. 16.7% with vehicle. BFRI stock is down 4.32% at $0.89.

Original reporting
rttnews.com
Published Oct 8, 2026, 2:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Biofrontera Files SNDA To Expand Ameluz Use In Actinic Keratosis; Stock Down — source image
Source · rttnews.com
Decision brief

The 30-second read

$BFRIBullishMed
01

Why it matters

The filing adds a new indication, potentially increasing the addressable market and revenue.

02

Market read

First report of a regulatory filing with supportive Phase 3 data; may drive short‑term price movement.

03

What to watch

Potential competition from other AK treatments and reimbursement uncertainties.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Biofrontera's Ameluz is already approved for basal cell carcinoma; the sNDA seeks broader AK indications.

Company-level read

Ticker impact

$BFRIBullishMedium confidence
Context

Biofrontera filed an sNDA to expand Ameluz for actinic keratosis, supported by positive Phase 3 trial results.

Expected impact

likely upward pressure as market prices in potential label expansion.

Evidence & confidence

The sNDA is a fresh regulatory event with clinical data; biotech stocks typically react positively to such filings.

Market effects

Sector

Expands the dermatology PDT market and may boost related device makers.

Regional

U.S. biotech sector sees incremental upside.

Global

Limited to companies with FDA-regulated dermatology products.

Counterpoint

What could challenge this read

If FDA requests additional data, the stock could face a sharp decline.

Key entities

  • company
    Biofrontera Inc.

    Biopharma developing photodynamic therapy products.

  • product
    Ameluz

    Topical gel used with BF‑RhodoLED lamp for PDT.

Read at source← All news

Also covered by

2 outlets

Related articles

OCT 8
$BFRIMedAI 8/10

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Biofrontera Inc. (NASDAQ: BFRI) submitted a supplemental New Drug Application to the FDA to expand Ameluz®'s use for treating actinic keratoses (AKs) to the full body, beyond the face and scalp. The submission follows a 12% revenue growth in 2025 and a 25% increase in the first half of 2026. The application is supported by clinical trial data showing 45.6% complete clearance of AK lesions. If approved, Ameluz® would be the only PDT approved in the U.S. for full-body AK treatment.

globenewswire.com2 min
SEP 28
$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Bristol Myers Squibb (BMY) awaits an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy. Egetis Therapeutics (EGTX) faces a Sept. 28 decision for Emcitate for MCT8 deficiency. Scholar Rock (SRRK), Biofrontera (BFRI), and Mirum Pharmaceuticals (MIRM) received early FDA approvals for their respective drugs. Mirum's shares rose 3% in pre-market trading.

newsable.asianetnews.com2 min
SEP 28
$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Await Key Rulings As BFRI, SRRK, MIRM Win Early Approvals

Bristol Myers Squibb (BMY) and Egetis Therapeutics (EGTX) await FDA decisions on drug expansions. Biofrontera (BFRI), Scholar Rock (SRRK), and Mirum Pharmaceuticals (MIRM) received early approvals. BMY's Camzyos, if approved, would be the first cardiac myosin inhibitor for adolescents with oHCM. EGTX's Emcitate could be the first FDA-approved treatment for MCT8 deficiency. SRRK and BFRI shares declined post-approval, while MIRM shares rose.

stocktwits.com2 min